(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 3.6MM | +3% |
Gross Profit | 132K | -78% |
Cost Of Revenue | 3.5MM | +20% |
Operating Income | -14.2MM | -9% |
Operating Expenses | 14.3MM | -11% |
Net Income | -14.3MM | -9% |
R&D | 4.2MM | -26% |
G&A | 5.5MM | +34% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Discover how DarioHealth Corp (DRIO) is shaping its future with significant B2B2C growth, high gross margins, and strategic partnerships in the first quarter of 2024.
DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the first quarter 2024.
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized Controlled Trial (RCT) demonstrating the impact of a digital stress reduction program for teens.
DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.
DarioHealth Corp. (NASDAQ:DRIO) Q4 2023 Earnings Call Transcript March 28, 2024 DarioHealth Corp. beats earnings expectations. Reported EPS is $-0.41, expectations were $-0.54. DRIO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the DarioHealth Fourth Quarter […]
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.